Status:

COMPLETED

Risk of Asymptomatic Cerebral Embolism During AF Ablation With AI-HPSD Strategy Versus Standard Settings

Lead Sponsor:

The Second Affiliated Hospital of Chongqing Medical University

Conditions:

Atrial Fibrillation

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The purpose of this prospective randomized controlled study is to evaluate the risk of asymptomatic cerebral embolism during catheter ablation of atrial fibrillation (AF) with AI-HPSD strategy versus ...

Detailed Description

Radiofrequency catheter ablation is increasingly performed in patients with paroxysmal and persistent atrial fibrillation (AF) in recent decade. However, catheter ablation of AF is associated with the...

Eligibility Criteria

Inclusion

  • Patients≥18 years of age prior to obtaining the written informed consent.
  • Patients with electrocardiographically documented, symptomatic atrial fibrillation.
  • Patients is scheduled to undergo circumferential pulmonary vein antrum radiofrequency ablation.
  • Patient or patient's legal representative is able and willing to give informed consent.

Exclusion

  • Moderate to severe valvular heart disease.
  • Contraindication for anticoagulation therapy.
  • Contraindication for Diffusion-Weighted MRI.
  • Ischemic stroke or transient ischemic attack within 6 months prior to the consent date.
  • Acute coronary syndrome within 3 months prior to the consent date.
  • Prior left atrial appendage occlusion device.
  • Prior septal occlusion device.
  • Left atrial size greater than 55 mm.
  • Conditions that prevent patient's participation in neurocognitive assessment (at physician's discretion).
  • Female patients who are pregnant or breast feeding or plan a pregnancy during the course of the study.
  • Simultaneous participation in another study.
  • Unwilling or unable to comply fully with the study procedures and follow-up requirements.

Key Trial Info

Start Date :

June 17 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2021

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT04408716

Start Date

June 17 2020

End Date

December 31 2021

Last Update

November 28 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Second Affilliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China, 400010